Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company's Board Of Directors

SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of respiratory and urologic disorders as well as chronic pain, today announced the election of K. Peter Hirth, Ph.D., to Afferent's Board of Directors. Dr. Hirth has more than 30 years of drug discovery and development experience in the biotechnology and pharmaceutical industries, and has built several successful biotech companies.

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.